Zobrazeno 1 - 10
of 1 400
pro vyhledávání: '"CEFTOLOZANE/TAZOBACTAM"'
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 38, Iss , Pp 216-222 (2024)
ABSTRACT: Objectives: Ceftolozane-tazobactam (C/T) is a combination of a cephalosporin and a β-lactamase inhibitor with activity against Gram-negative bacilli (GNB). The study aims were to evaluate the activity of C/T in vitro vs. comparators agains
Externí odkaz:
https://doaj.org/article/394ee0cab1a54a768b0fde7ca69ed98b
Autor:
Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher Longshaw
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 8 (2024)
ABSTRACT Carbapenem-resistant Enterobacterales represent a major health threat and have few approved therapeutic options. Enterobacterales isolates were collected from hospitalized inpatients from 49 sites in six European countries (1 January–31 De
Externí odkaz:
https://doaj.org/article/1f3d1d994d1a4cbbb99acb1bfe3c5808
Autor:
Chien-Ming Chao, Wen-Liang Yu
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e33114- (2024)
Ceftolozane, a novel cephalosporin, combined with tazobactam, a known β-lactamase inhibitor, shows robust antipseudomonal activity, although it doesn't cover carbapenemases. Our review of data from 2012 to 2021 in Taiwan highlights TOL/TAZ's in-vitr
Externí odkaz:
https://doaj.org/article/047ae70b731e4b9681647a6ba57ad645
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens. Ceftolozane/tazobactam demonstrated efficacy comparable to meropenem in patients with v
Externí odkaz:
https://doaj.org/article/a8dff5c954aa47928cb219cb8dfc6a54
Autor:
Mihai Octavian Dan, Daniela Tǎlǎpan
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
Gram-negative bacteria have been one of the most studied classes in the field of microbiology, especially in the context of globally alarming antimicrobial resistance levels to these pathogens over the course of the past decades. With high numbers of
Externí odkaz:
https://doaj.org/article/3ed6ca5f04ad4a6f826945a9201cc14c
Autor:
Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Rania El Lababidi, Diaa Alrahmany, Islam M. Ghazi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, Jihad Mallat
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 699 (2024)
The optimal doses of ceftazidime–avibactam (CZA) and ceftolozane–tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established. Hence, the objec
Externí odkaz:
https://doaj.org/article/80d5d2a1c0414dcb8eb4d9060cb58a55
Autor:
Jan Thomas De Pourcq, Adria Riera, Laura Gras, Noe Garin, Maria Antònia Busquets, Joana Cardenete, Daniel Cardona, Pau Riera
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 896 (2024)
Ceftolozane-tazobactam (CT) is used for the treatment of complicated infections and for multidrug-resistant strains of Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing enterobacteria. In certain cases, simultaneous administration
Externí odkaz:
https://doaj.org/article/c2ff000b31cf46feb0f798deda850781
Autor:
Diogo Mendes Pedro, Sérgio Eduardo Paulo, Carla Mimoso Santos, Ana Bruschy Fonseca, José Melo Cristino, Álvaro Ayres Pereira, Cátia Caneiras
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
IntroductionExtensively drug-resistant Pseudomonas aeruginosa (XDR-PA) is a growing concern due to its increasing incidence, limited therapeutic options, limited data on the optimal treatment, and high mortality rates. The study aimed to characterize
Externí odkaz:
https://doaj.org/article/e9d028aace6d43fab7e09a3d88205f84
Autor:
James A. Karlowsky, Mark G. Wise, Tai-Chin Hsieh, Hung-Chi Lu, Wei-Ting Chen, Ming-Huei Cheng, Fakhar Siddiqui, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 34, Iss , Pp 106-112 (2023)
ABSTRACT: Objectives: To determine the in vitro activities of ceftolozane/tazobactam (C/T) and comparators against Pseudomonas aeruginosa isolates cultured from hospitalised patient samples in Taiwan from 2012 to 2021 with an additional focus on the
Externí odkaz:
https://doaj.org/article/3e5e47fbc6ff4a82ae065a886c5d8f5b
Publikováno v:
Microbes and Infectious Diseases, Vol 4, Iss 3, Pp 894-904 (2023)
Background: Multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa) is a major public health threat. Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are active against many MDR P. aeruginosa, and can improve the management of in
Externí odkaz:
https://doaj.org/article/9adc72f59d584c498171a3792d910874